A new radiotracer – an injected compound used in PET scans – could help inform doctors that a patients aggressive cancer will not respond to chemotherapy before treatment is given.
A ‘mini-protein’ can deliver radiation doses directly to tumours without harming healthy tissues. The approach shows promise for the treatment of metastatic bladder cancer and other tumours.
To diagnose neuroblastoma in children, lengthy scans and anaesthesia are often required. A new PET/CT imaging technique could deliver faster results without sedation for the paediatric patients.
Radiotherapy of prostate cancer often comes with side effects, causing some patients to discontinue treatment. New research shows the benefits of at lowering the dose over subsequent treatment cycles.
The nuclear medicine global market is projected to see a significant increase in the coming years, with the lion's share being attributed to radiotherapeutics. So, how to set up a dedicated theranostics centre? At the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Toronto, Ontario, an entire session was dedicated to planning logistics, radiation safety, and…
The new Nuclear Medicine Department of the San Pietro Fatebenefratelli Hospital was inaugurated in Rome. The Department was inaugurated with the online intervention of Health Minister Orazio Schillaci and in the presence of Maria Tripodi (Undersecretary at the Ministry of Foreign Affairs and International Cooperation), Antonello Aurigemma (President of Lazio Regional Council).
A new radiotracer enables positron emission tomography (PET) scans to be used for the first time to accurately pinpoint when and where tuberculosis (TB) is still active in a patient’s lungs.
What is an advanced clinical practitioner (ACP) and why should nuclear medicine technologists strive to become one? At the 2024 annual meeting of the SNMMI in Toronto, ACP Luisa Roldão Pereira outlined the position and its importance in the clinical context.
The IRCCS in Bologna has inaugurated a state-of-the-art integrated PET/CT system. This cutting-edge technology allows for the entire human body to be studied in a single scan, even detecting the smallest tumour cells.
A new study suggests superiority of the novel investigational PET imaging agent ⁶⁸Ga-DPI-4452 (Debio 0328) to standard CT imaging in the context of clear cell renal cell cancer (ccRCC).
In some patients with multiple sclerosis (MS), symptoms worsen during treatment, but MRI scans do not indicate any change. In such cases, positron emission tomography could help, a new study suggests.
A new SPECT/CT imaging technique using lead-212 (²¹²Pb) shows promise in targeted alpha therapy (TAT) for patients with metastatic castration-resistant prostate cancer.
Multiplex PET imaging technology could provide a ground-breaking new approach for diagnosing and treating bowel cancer patients, according to scientists in Glasgow.
Dutch researchers use PSMA targeting to improve detection of prostate cancer, improving nodal staging and guiding more accurate surgery for this important patient population.
Breast cancer has no “one size fits all” therapy approach: subtypes differ significantly in malignancy, progression, and treatment response. Therefore, the more is known about the type of carcinoma in a patient, the better the outcome. At the annual scientific EUSOBI meeting in Valencia, Dr Ramona Woitek pointed out the potential of novel imaging techniques and computational image analysis…
United Imaging Healthcare Europe, a leading company in advanced medical imaging and radiotherapy equipment, proudly announces the introduction of its first Mobile Digital PET/CT solution in Italy, now fully operational in the Piacenza province under the auspices of the Azienda Unità Sanitaria Locale Piacenza (AUSLP) hospital.
Bone scans have been found to overstage prostate cancer at initial staging compared to prostate specific membrane antigen (PSMA) PET, according to new research.
A new imaging agent can predict early metabolic response to HER2-targeted treatment in metastatic breast cancer patients, according to new research published in the Journal of Nuclear Medicine.
A new PET tracer, 89Zr-DFO-girentuximab, can accurately detect a type of kidney cancer called clear cell renal cell carcinoma and differentiate it from other types of kidney tumors.
